Cover Image
市場調查報告書

E3泛素蛋白接合酶XIAP:開發中產品分析

E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364854
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
E3泛素蛋白接合酶XIAP:開發中產品分析 E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 64 Pages
簡介

本報告提供以E3泛素蛋白接合酶XIAP為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

E3泛素蛋白接合酶XIAP 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Ascentage Pharma Group Corporation, Ltd.
  • Astex Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Debiopharm International SA
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • 武田藥品工業

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0143TDB

Summary

Global Markets Direct's, 'E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016', provides in depth analysis on E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted pipeline therapeutics.

The report provides comprehensive information on the E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)
  • The report reviews E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Overview
  • Therapeutics Development
    • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Stage of Development
    • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Therapy Area
    • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Indication
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Companies
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Products under Development by Universities/Institutes
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Companies Involved in Therapeutics Development
    • Ascentage Pharma Group Corporation, Ltd.
    • Astex Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Debiopharm International SA
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Drug Profiles
    • ASTX-660 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Debio-1143 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-1200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 to Inhibit XIAP for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit XIAP and c-IAP for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit XIAP for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit XIAP for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit XIAP for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-3256336 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • xaripin D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • xaripin P - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Dormant Projects
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Discontinued Products
  • E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Featured News & Press Releases
    • Jun 07, 2016: Debiopharm International initiates clinical Phase II study evaluating Debio 1143 in Ovarian Cancer
    • Jun 02, 2016: FDA grants Orphan Drug Designation to Debiopharm International SA's IAP inhibitor Debio 1143 in the treatment of ovarian cancer
    • Dec 08, 2015: EMA grants Orphan Drug Designation to Debiopharm International's IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer
    • Nov 03, 2015: Debiopharm International presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143 at the 27th EORTC-NCI-AACR symposium in Boston
    • Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies
    • Apr 16, 2015: Debiopharm International announces results of key oncology program, Debio 1143 at 2015 AACR Conference
    • Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
    • Nov 18, 2014: Debiopharm Group Presents Advances Of key Oncology Product On Debio 1143 Clinical Program At The 26th EORTC-NCI-AACR Symposium In Barcelona
    • May 28, 2014: Debiopharm tp present data on Debio 1143 at the 50th ASCO Annual Meeting
    • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    • Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies
    • Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent
    • Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent
    • Mar 29, 2011: University Of Michigan Researchers Discover New Cancer Drug, AT-406
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Ascentage Pharma Group Corporation, Ltd., H1 2016
  • Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Pipeline by Debiopharm International SA, H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top